Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexcom’s Q2 Earnings Exceed Wall Street Expectations; Holds G7 Launch

Executive Summary

Dexcom expects 2020 revenues to reach $1.85bn driven by new patient adoption of its CGM device, but will not launch its next-gen G7 this year. 

You may also be interested in...



Dexcom Outlines Three-Pronged Growth Strategy To Reach $4-4.5BN Revenue Goal By 2025

Dexcom’s growth strategy includes growing its core business, expanding into pharmacy sales channel, and expanding into new markets.

Beyond Diabetes: Abbott Launches Glucose Sport Biosensor For Athletes To Track Blood Sugar

Analyst Larry Biegelsen expects Abbott’s CGM move into the consumer market could open a large new marketing opportunity.

Abbott Sees Signs Of Post-Pandemic Recovery In Q2

Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel